AHPA Avista Public Acquisition Corp. II Class A
Organogenesis Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
On 3/23/2022 the company announced a proposed merger with OmniAb, Ligand’s antibody discovery business.
$6.13 -0.63 (-9.26%)
As of 11/01/2022 16:00:00 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: Common stocks
Category3: Micro cap
GICS sector: Financials
Industry: Shell Companies
Index country: USA
Country of incorporation:
IPO date: 09/30/2021
Outstanding shares: 23,000,000
Average volume: 65,979
Market cap: $140,875,000
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Quarterly filings: 10-Q
Annual filings: 10-K
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%